1Levine MM,Pierce NF.Cholera,edited by Dhiman Barua and William B.Greenough Ⅲ.Pleum Medical book Company,New York[J].Immunity and Vaccine Development,1992,285-327.
3Mosley WH,Mccormack WM,Fahimuddin M,et al.Report of the 1966-1967 cholera vaccine field trial in rural East Pakistan 1.Study design and results of first year of observation[J].Bull WHO,1969,40:177-185.
4Philippines Cholera Committee.A controlled field trial of the effectiveness of cholera and cholera El Tor vaccines in the Philippines[J].Bull WHO,1965,32:603-625.
5Saroso JS,Bahrawi W,Witjaksono H,et al.A controlled field trialof plain and alumimum hydroxide-absorbed cholera vaccines in Surabaya,Indonesia,during 1973-1975[J].Bull WHO,1978,56:619-727.
6Levine MM,Kaper JB,Black RE,et al.New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development[J].Microbiol Rev,1983,47:510-550.
7Manas CN.Vibriocidal antibody and antibodies to Vibrio cholerae lipopolysaccharide,cell-bound heamagglutinin and toxin in Thai Population[J].Southeast Asian J Trop Med Pub Hlth,1986,17:558.
9Viret JF,Favre D,Wegmuller B,et al.Mucosal and systemic immune responses in humans after primary and booster immunizations with orally administered invasive and noninvasive live attenuated bacteria[J].Infection and Immunity,1999,67:3 680-3 685.
1Chu Chiayung,Liu Baokui,Watson D.Preparation,characterization,and immunogenicity of conjugates composed of the Ospecific polysaccharide of Shigella dysenteriae type 1(Shiga's Bacillus)bound to tetanus toxoid[J].Infect Immun,1991,59(12):4450--4458.
2Gupta R K,Szu S C,Finkelistein R K,et el.Synthesis,characterization,and some immunological properties of conjugates composed of the detoxified lipopolysaccharide of Vibrio cholerae O1 serotype Inaba bound to cholera toxin[J].Infect Immun,1992,60(8):3201-3208.
3Tsai Chao-ming,Frasch C E.A sensitive silver stain for detecting lipopolysaccharides in polyacrylamide gels[J].Anal Biochem,1982,119:115-119.
